Xention Introduces Metrion Biosciences
News May 13, 2015
Xention Limited the Cambridge-based biopharmaceutical company specialising in the development of new drugs for atrial fibrillation, announced today the launch of Metrion Biosciences, a contract screening business focused on providing comprehensive and high quality ion channel services to the pharma and biotech industry.
Photograph of Dr Marc Rogers, VP Research.
The Metrion Biosciences team, led by Dr Marc Rogers, VP Research, has extensive experience of ion channel research, having brought five new Xention ion channel drug candidates to the clinic, conducted multiple research collaborations with international pharma businesses, and completed several UK and European grant projects. Dr Rogers is assisted by experienced ion channel Principal Scientists Dr Kathy Sutton and Dr Rob Kirby.
Metrion Biosciences intends to launch a new panel of in vitro cardiac ion channel and human cardiomyocyte assays for better detection of cardiac safety risks in new drugs, and will work towards full accreditation of its panel under the FDA’s new Comprehensive In Vitro Proarrhythmia Assay initiative (CIPA). In addition, Metrion will market its panel of neurological ion channel assays for pharmaceutical companies to profile and de-risk new drug candidates.
Small Tweak Makes Progress Towards Improved Flu TreatmentNews
Researchers report that a tweak to a small-molecule drug shows promise for future production of new antiviral therapies that could help patients, regardless of the strain with which they are infected.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Comments | 0 ADD COMMENT
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018